Amino Mari, Yoshioka Koichiro, Iwata Osamu, Fujikura Hisanori, Deguchi Yoshiaki, Ban Kazunobu, Shiina Yutaka, Goto Shinya, Handa Shunnosuke, Tanabe Teruhisa, Nakagawa Yoshihide, Morita Seiji, Iwase Hirotada, Yamamoto Isotoshi, Inokuchi Sadaki, Marutani Yoshinori
Department of Cardiology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa 259-1193.
J Cardiol. 2003 Mar;41(3):127-34.
Class I antiarrhythmic agents are not always effective in the treatment of life-threatening ventricular tachycardia/ventricular fibrillation (VT/VF) especially in patients with cardiopulmonary arrest. Nifekalant hydrochloride(NIF) is a novel class III antiarrhythmic agent for malignant VT/VF. This study prospectively evaluated NIF efficacy for life-threatening VT/VF observed after cardiopulmonary arrest.
Thirty-two of 145 patients who were transferred to the emergency room in Tokai University Hospital showed VT/VF after resuscitation from cardiopulmonary arrest from June 2000 to March 2001. These 32 patients were treated with 12 mg (mean) epinephrine and 1.0-2.0 mg/kg lidocaine following direct current application(200 to 360J), and then classified into two groups. Eleven patients received intravenous 0.15 to 0.3 mg/kg NIF followed by intravenous infusion of 0.3 to 0.4 mg/kg/hr NIF(NIF group). The other 21 patients received 1.0 to 2.0 mg/kg of lidocaine(non-NIF group).
Sinus rhythm was restored in the nine patients(82%) in the NIF group but only four patients (19%) in the non-NIF group. QTc was not prolonged(0.45 +/- 0.04 sec, n = 9) and no torsades de pointes was observed in the NIF group. Two patients survived but the remaining nine patients died in the NIF group. Five patients died of cardiac standstill following sinus bradycardia and repeated sinus arrest within 2 to 27 hr after admission, two patients died of sudden cardiac arrest from sinus rhythm, and two patients died of persistent VT/VF. In contrast, all 21 patients in the non-NIF group died. Seventeen patients died of persistent VT/VF before hospitalization, one patient died of recurrent VT/VF, and three patients died of cardiac standstill following sinus bradycardia.
NIF effectively suppresses VT/VF which is refractory to direct current shock in patients with cardiopulmonary arrest. However, NIF may rather worsen electrophysiological function in the sinus node after administration of high doses of epinephrine, and may induce sinus bradycardia and/or sinus arrest. Careful observation, such as monitoring of electrocardiography and blood pressure and temporary cardiac pacemaker use, is needed to prevent death in patients surviving after cardiopulmonary arrest if NIF is administered following high dose epinephrine infusion.
I类抗心律失常药物在治疗危及生命的室性心动过速/心室颤动(VT/VF)时并不总是有效,尤其是在心脏骤停患者中。盐酸尼非卡兰(NIF)是一种用于治疗恶性VT/VF的新型III类抗心律失常药物。本研究前瞻性评估了NIF对心脏骤停后观察到的危及生命的VT/VF的疗效。
2000年6月至2001年3月期间,在东海大学医院急诊科接受心肺复苏后出现VT/VF的145例患者中,有32例患者。这32例患者在直流电除颤(200至360J)后接受了12mg(平均)肾上腺素和1.0 - 2.0mg/kg利多卡因治疗,然后分为两组。11例患者静脉注射0.15至0.3mg/kg NIF,随后静脉输注0.3至0.4mg/kg/hr NIF(NIF组)。另外21例患者接受1.0至2.0mg/kg利多卡因治疗(非NIF组)。
NIF组9例患者(82%)恢复窦性心律,而非NIF组仅4例患者(19%)恢复窦性心律。NIF组QTc未延长(0.45±0.04秒,n = 9),未观察到尖端扭转型室速。NIF组2例患者存活,其余9例患者死亡。5例患者在入院后2至27小时内因窦性心动过缓和反复窦性停搏死于心脏停搏,2例患者因窦性心律突然心脏骤停死亡,2例患者因持续性VT/VF死亡。相比之下,非NIF组的21例患者全部死亡。17例患者在住院前死于持续性VT/VF,1例患者死于复发性VT/VF,3例患者因窦性心动过缓后心脏停搏死亡。
NIF能有效抑制心脏骤停患者对直流电休克难治的VT/VF。然而,在大剂量肾上腺素给药后,NIF可能会使窦房结的电生理功能恶化,可能诱发窦性心动过缓和/或窦性停搏。如果在大剂量肾上腺素输注后给予NIF,需要仔细观察,如监测心电图和血压以及使用临时心脏起搏器,以防止心脏骤停后存活患者死亡。